BioLife Solutions

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioLife Solutions reports record revenue and projects strong growth

BioLife Solutions delivered strong financial performance in Q4 2022, with record revenue and growth across key revenue platforms.
Despite challenges in operating expenses and gross margin, the company remains optimistic about future growth and profitability.
By focusing on high-margin revenues, supply chain enhancements, and allogeneic therapies, BioLife is strategically positioned for long-term success.

BioLife Solutions reports revenue growth and strategic business evaluation

BioLife Solutions reported solid Q1 2023 performance with revenue growth and improved gross margin, despite short-term EBITDA challenges.
The company is strategically evaluating underperforming businesses while focusing on high-margin recurring revenue streams for future growth.
CEO's balanced approach of maintaining strengths and exploring new projects signals a commitment to sustainable profitability and innovation.
BioLife's emphasis on efficiency and strategic planning positions it well for navigating market uncertainties and driving long-term success.

BioLife Solutions reports Q2 revenue decline, focuses on strategic growth

BioLife Solutions navigated challenges in Q2 2023 with a strategic focus on higher-margin streams and a strong pipeline for growth.
Despite a decrease in revenue and challenges in key markets, the company's divestiture plans and revenue guidance reflect confidence in future performance.
Analysts' concerns about capacity constraints and operational challenges highlight areas for improvement and strategic focus for BioLife Solutions.

BioLife Solutions faces revenue decline in Q3 but eyes market growth

BioLife Solutions navigated challenges in Q3 2023 with a decline in revenue and negative adjusted EBITDA, but remains optimistic about its market position and potential for revenue recovery. Strategic divestiture plans and a focus on core products aim to drive profitability and growth.

BioLife Solutions reports 11% revenue decrease in 2023

BioLife Solutions navigated revenue challenges in 2023, with a focus on higher margin revenue streams and operational efficiency.
Despite revenue declines, the company remains optimistic about future growth opportunities in the cell processing sector.
Proactive supply chain management and a diversified supplier base position BioLife well to mitigate risks and ensure operational continuity.
Strategic plans to divest underperforming product lines and optimize operations indicate a path towards improved financial performance.

BioLife Solutions excels in Q3, shifts focus to high-margin CGT tools

BioLife Solutions demonstrated robust performance in Q3 2024, driven by strong revenue growth and strategic divestment decisions.
The company's focus on becoming a pure-play CGT tools provider and emphasis on high-margin products signal a clear strategic direction.
While facing challenges in transitioning its business model, BioLife is well-equipped to capitalize on opportunities in the growing biopreservation market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate BioLife Solutions, Inc. (BLFS) to Report a Decline in Earnings: What to Look Out for

BOTHELL, Wash., Oct. 26, 2021 /PRNewswire/ -- Biolife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for cell and gene therapies ("CGT"), and its biological material storage brand SciSafe, a multi-facility provider of storage services to the CGT and broader biopharma market, today announced the opening of a new 40,000 square-foot biorepository Center of Excellence in Amsterdam, adjacent to the Schiphol Airport.

Biolife Solutions Supports Biostorage Best Practices Through SciSafe's "Centers of Excellence" With New World-Class Facility in Amsterdam

This company is preserving biological material and can help your portfolio grow.

Have $500? This Under-the-Radar Stock Could Make You Richer From the Biotech Boom

BOTHELL, Wash., Oct. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced a broad engagement with a leading cell therapy developer, wherein BioLife's CryoStor freeze media, evo cold chain management platform and SciSafe storage services with Stirling UltraCold freezers are all being utilized by this top 10 largest global pharmaceutical company to support the anticipated regulatory approval and commercial launch of a new CAR T-cell therapy.

BioLife Solutions Leverages Expanded Bioproduction Tools and Services Portfolio in Multipoint Engagement with Leading CAR T-Cell Developer

Aby Mathew, Exec VP And Chief Scientific Off at Biolife Solutions (NASDAQ:BLFS), made a large buy and sell of company shares on September 22, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Aby Mathew exercised options to purchase 20,000 Biolife Solutions shares at a price of $1.64 per share for a total of $32,800 on September 22.

Notable Biolife Solutions Insider Trades $971 Thousand In Company Stock

BOTHELL, Wash., Sept. 20, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that Joydeep Goswami, Chief Strategy and Corporate Development Officer at Illumina, will join its board of directors on October 1, 2021.

BioLife Solutions Appoints Joydeep Goswami, MBA, PhD to Board of Directors

BOTHELL, Wash., Sept. 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that Roderick de Greef, Chief Financial Officer, plans to retire on December 31, 2021 after a distinguished career with the Company.

BioLife Solutions Announces CFO Retirement

The company, which specializes in cold-storage solutions for biotechs, had a hot month.

Why Shares in BioLife Solutions Jumped 24.4% in August

BOTHELL, Wash., Sept. 1, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, announces that it has filed a registration statement on Form S-3 with the Securities and Exchange Commission ("SEC") to register approximately 10.7 million shares of restricted common stock held by stockholders of previously acquired companies Global Cooling, Inc. (operating as Stirling Ultracold), SciSafe Holdings, Inc. and Sexton Biotechnologies, Inc., as well as certain shares held by Casdin Capital.

BioLife Solutions Files Form S-3 Registration Statement to Register Shares from Completed Acquisitions

BOTHELL, Wash., Sept. 1, 2021 /PRNewswire/ --  BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies.

BioLife Solutions Closes Acquisition of Sexton Biotechnologies

The stock price of BioLife Solutions Inc (NASDAQ: BLFS) increased by 19.62% today. This is why it happened.

BLFS Stock: 19.62% Increase Explanation

Cassava Sciences Inc

Don't let these companies fly under your radar.

2 Little-Known Nasdaq Stocks Making Big Moves Wednesday

BOTHELL, Wash., Aug. 25, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that its common stock will be added to the S&P SmallCap 600 Index effective prior to the opening of trading on Monday, August 30, 2021.

BioLife Solutions Joins S&P SmallCap 600 Index

The company enjoys strong secular tailwinds from a growing regenerative medicine market, gaining lots of new customers and seeing existing customers move through clinical phases. Acquisitions have added significantly to the TAM and provided multiple leverage opportunities, especially in sales.

BioLife Solutions: The Whole Is Much More Than The Sum Of The Parts

BioLife Solutions' (BLFS) CEO Mike Rice on Q2 2021 Results - Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 480.00% and 10.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Top Estimates

Shares of BioLife Solutions (NASDAQ:BLFS) moved higher by 4.2% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 100.00% over the past year to ($0.00), which beat the estimate of ($0.07).

Recap: BioLife Solutions Q2 Earnings

BOTHELL, Wash., Aug. 12, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced financial results for the three and six months ended June 30, 2021.

BioLife Solutions Announces Second Quarter 2021 Financial Results

INDIANAPOLIS, Aug. 9, 2021 /PRNewswire/ -- Sexton Biotechnologies, a provider of novel manufacturing solutions for the cell and gene therapy (CGT) industry, today announced that it has entered into a definitive agreement whereby BioLife Solutions (NASDAQ: BLFS) will acquire all outstanding shares of the company in a deal worth a total value of $30 million. During the past two years, Sexton has worked to provide end-to-end solutions for emerging cell and gene therapy manufacturers.

Sexton Biotechnologies to be Acquired by Biolife Solutions

BOTHELL, Wash., Aug. 9, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has entered into a definitive agreement to acquire all remaining outstanding shares of privately held Sexton Biotechnologies, Inc., that it does not currently own, for $24.0 million, in consideration for 506,382 newly issued shares of BioLife common stock.

BioLife Solutions to Acquire Sexton Biotechnologies to Expand Cell and Gene Therapy Tools Portfolio

BOTHELL, Wash., Aug. 5, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that the Company's second quarter 2021 financial results will be released after market close on Thursday, August 12, 2021, and that the Company will host a conference call and live webcast at 4:30 p.m.

BioLife Solutions to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021

BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

BOTHELL, Wash., July 14, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced changes to its board of directors.

BioLife Solutions Announces Changes to Board of Directors

BioLife Solutions, Inc. is a developer, manufacturer, and marketer of bioproduction tools and services for the cell and gene therapy industry.

BioLife Solutions: Cryobiology Specialist, Aggressive M&A-Led Triple-Digit-Growth Ahead

There is a growing prominence in the cell and gene-based therapy sector. Logistic providers of the aforesaid sector are enjoying huge revenue surges.

News for BioLife Solutions Stock (BLFS)